ReviewCurrent cardiology reports2025
In-Stent Restenosis: Incidence, Mechanisms, and Treatment Options.
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Stress hyperglycemia ratio in coronary artery disease: a systematic review and meta-analysis of severity and prognosis.Cardiovascular diabetology · 2026Pooled it
- Influencing Factors and Prediction Model Construction of Anxiety and Depression in Patients With Coronary Heart Disease Undergoing In-Stent Restenosis.Actas espanolas de psiquiatria · 2026Article
- Exploring the relationship between novel serum inflammatory markers, non-traditional lipid parameters, and in-stent restenosis after percutaneous coronary intervention: a single-center retrospective study.Frontiers in cardiovascular medicine · 2026Article
- Association between the composite nutritional index TCBI and ISR.Frontiers in nutrition · 2026Article
- Efficacy and Mid-Term Outcomes of Paclitaxel-Coated Balloon (OptilumeJournal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo provide an overview of up-to-date treatment practices for in-stent restenosis (ISR). RECENT
findingsISR is treated with similar effectiveness by paclitaxel drug coated balloons and second-generation drug eluting stents. Sirolimus coated balloons are an emerging technology that requires further investigation. The management of ISR remains challenging even with the newest generation of drug-eluting stents. The use of intravascular imaging is highly recommended to identify the mechanisms of stent failure and to tailor the method of treatment, whether it is plain old balloon angioplasty, plaque/calcium modifying tools such as intravascular lithotripsy or rotational atherectomy, additional drug eluting stents, or drug coated balloons. Paclitaxel drug coated balloons are the most recent technological advancement which has provided an option to treat ISR that doesn't require further layers of metal. Currently, other drug coatings are being studied but it is unclear whether these balloons are as effective as paclitaxel coated balloons, with ongoing trials designed to answer this question.
Indexed as
Identifiers
40536538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.